Answers are grounded in this paper and cite their sources.
Intervertebral disc degeneration (IVDD) is a chronic and progressive musculoskeletal disorder characterized by excessive extracellular matrix (ECM) degradation and nucleus pulposus cell (NPC) dysfunction, ultimately contributing to disc structural failure and low back pain (LBP). Exosomes are nanometer-scale extracellular vesicles secreted by various cell types and serve as important mediators of intercellular communication by transporting bioactive molecules, including proteins, lipids, and nucleic acids. Owing to their low immunogenicity, biocompatibility, and amenability to engineering, exosomes have attracted interest as cell-free therapeutic candidates. This review summarizes and critically appraises preclinical evidence on exosomes derived from various cell sources in experimental models of IVDD, distinguishing experimentally demonstrated effects from proposed mechanisms. We discuss the regulatory pathways attributed to exosome-mediated communication within the degenerative disc microenvironment, together with the methodological limitations of current studies, including incomplete extracellular vesicle characterization, simplified in vitro models, and short-term rodent models. Because evidence from human clinical samples remains scarce, the review focuses on therapeutic rather than diagnostic applications, and it outlines the evidence on product standardization, intradiscal delivery, dosing, and long-term safety that will be required before exosome-based therapies can be evaluated clinically.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: